Medullary Thyroid Carcinoma Clinical Trial
Official title:
A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
This is a single-arm, open-label, multicenter study designed to evaluate the preliminary antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in patients with medullary thyroid cancer (MTC).
A total of approximately 30 patients with MTC will be enrolled. The patients will undergo a 3 weeks-on and 1week-off treatment scheme with HA121-28 tablets 450 mg orally once daily in the 28-day cycle until disease progression or intolerable toxic reaction, whichever occurs first. During the administration of HA121-28 tablets, vital signs, physical examination, ECOG performance status, hematology and chemistry test, ECG, adverse events and concomitant drugs will be evaluated every four weeks, an additional ECG will be observed two weeks after the first dose, calcitonin and pregnancy test will be performed every 8 weeks. CT for tumor assessment will be performed every 8 weeks for the first year, and every 12 weeks thereafter. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03636945 -
Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma
|
N/A | |
| Withdrawn |
NCT01736878 -
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
|
Phase 2 | |
| Completed |
NCT06067594 -
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
|
||
| Active, not recruiting |
NCT04970134 -
Spanish Study for Molecular Characterization of Thyroid Carcinoma
|
||
| Completed |
NCT01424878 -
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
|
||
| Completed |
NCT02586350 -
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
|
Phase 2/Phase 3 | |
| Completed |
NCT00514046 -
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01730638 -
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT01511393 -
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
|
||
| Terminated |
NCT00923247 -
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
|
Phase 1/Phase 2 | |
| Completed |
NCT00880503 -
Collection of Tissue Samples for Study of Multidrug Resistance
|
||
| Not yet recruiting |
NCT06121271 -
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
|
Phase 2 | |
| Completed |
NCT03246659 -
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC
|
Phase 1 | |
| Recruiting |
NCT05534594 -
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
|
N/A | |
| Not yet recruiting |
NCT01373736 -
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
|
Phase 3 |